MEM 1003: Completed Phase IIa enrollment

MEMY completed enrollment in a double-blind, U.S. Phase IIa trial in 180 patients. The trial will compare 30 or 90 mg of twice-daily MEM 1003 to placebo after 12 weeks. Patients will then be evaluated...